DK1551868T3 - Faktor involveret i metastase og anvendelser deraf - Google Patents

Faktor involveret i metastase og anvendelser deraf

Info

Publication number: DK1551868T3
Authority: DK; Denmark
Prior art keywords: metastasis; polypeptide; amino acid; extracellular matrix; sequence according
Prior art date: 2002-10-18

Application number

DK03769423T

Other languages

English (en)

Inventor

Anke Klippel-Giese

Joerg Kaufmann

Rolf Schwarzer

Original Assignee

Silence Therapeutics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-18

Filing date

2003-10-20

Publication date

2009-04-20

2003-10-20 Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag

2009-04-20 Application granted granted Critical

2009-04-20 Publication of DK1551868T3 publication Critical patent/DK1551868T3/da

Links

206010027476 Metastases Diseases 0.000 title abstract 2
230000009401 metastasis Effects 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 4
230000008569 process Effects 0.000 abstract 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 2
210000002744 extracellular matrix Anatomy 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
208000005623 Carcinogenesis Diseases 0.000 abstract 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
230000031018 biological processes and functions Effects 0.000 abstract 1
230000036952 cancer formation Effects 0.000 abstract 1
231100000504 carcinogenesis Toxicity 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
230000012292 cell migration Effects 0.000 abstract 1
230000009087 cell motility Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000007946 glucose deprivation Effects 0.000 abstract 1
230000004153 glucose metabolism Effects 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000003938 response to stress Effects 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Neurology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK03769423T 2002-10-18 2003-10-20 Faktor involveret i metastase og anvendelser deraf DK1551868T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02023384		2002-10-18
PCT/EP2003/011604 WO2004035615A2 (en)	2002-10-18	2003-10-20	Factor involved in metastasis and uses thereof

Publications (1)

Publication Number	Publication Date
DK1551868T3 true DK1551868T3 (da)	2009-04-20

Family

ID=32103889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03769423T DK1551868T3 (da)	2002-10-18	2003-10-20	Faktor involveret i metastase og anvendelser deraf

Country Status (19)

Country	Link
US (2)	US20060240022A1 (da)
EP (2)	EP2072619A1 (da)
JP (2)	JP4820092B2 (da)
KR (1)	KR101154130B1 (da)
CN (1)	CN100564524C (da)
AT (1)	ATE420102T1 (da)
AU (2)	AU2003278112A1 (da)
BR (1)	BR0315411A (da)
CA (1)	CA2501333A1 (da)
CY (1)	CY1110313T1 (da)
DE (1)	DE60325754D1 (da)
DK (1)	DK1551868T3 (da)
ES (1)	ES2319891T3 (da)
IL (1)	IL167801A (da)
MX (1)	MXPA05004134A (da)
PT (1)	PT1551868E (da)
SI (1)	SI1551868T1 (da)
WO (1)	WO2004035615A2 (da)
ZA (1)	ZA200502483B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7405292B2 (en)	2002-02-19	2008-07-29	The Children's Hospital Of Philadelphia	Cellular genes regulated by HIV-1 infection and methods of use thereof
DE60310944T3 (de)	2002-08-05	2017-08-03	Silence Therapeutics Gmbh	Weitere neue formen von interferierende rns moleküle
AU2003278112A1 (en) *	2002-10-18	2004-05-04	Silence Therapeutics Ag	Factor involved in metastasis and uses thereof
EP2319925B1 (en)	2004-08-16	2018-07-25	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801
CN100357323C (zh) *	2006-01-05	2007-12-26	清华大学	一种细胞迁移相关蛋白及其编码基因与应用
NL2000439C2 (nl) *	2006-01-20	2009-03-16	Quark Biotech	Therapeutische toepassingen van inhibitoren van RTP801.
US7825099B2 (en)	2006-01-20	2010-11-02	Quark Pharmaceuticals, Inc.	Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
FR2898908A1 (fr)	2006-03-24	2007-09-28	Agronomique Inst Nat Rech	Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
WO2008054534A2 (en)	2006-05-11	2008-05-08	Quark Pharmaceuticals, Inc.	Screening systems utilizing rtp801
US7872119B2 (en)	2007-02-26	2011-01-18	Quark Pharmaceuticals, Inc.	Inhibitors of RTP801 and their use in disease treatment
WO2010021720A1 (en)	2008-08-19	2010-02-25	Nektar Therapeutics	Conjugates of small-interfering nucleic acids
WO2011035065A1 (en)	2009-09-17	2011-03-24	Nektar Therapeutics	Monoconjugated chitosans as delivery agents for small interfering nucleic acids
EP2895607B1 (en)	2012-09-12	2021-05-05	Quark Pharmaceuticals, Inc.	Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2259800T3 (es)	1990-06-11	2006-10-16	Gilead Sciences, Inc.	Procedimientos de uso de ligandos de acido nucleico.
DE59708838D1 (de)	1996-08-30	2003-01-09	Jens Peter Fuerste	Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
EP1071753A2 (en)	1998-04-20	2001-01-31	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US5958773A (en) *	1998-12-17	1999-09-28	Isis Pharmaceuticals Inc.	Antisense modulation of AKT-1 expression
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2382748A1 (en) *	1999-06-11	2000-12-21	Human Genome Sciences, Inc.	50 human secreted proteins
US6133032A (en) *	1999-09-09	2000-10-17	Isis Pharmaceutical Inc.	Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en)	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Rna interference by modified short interfering nucleic acid
ES2336887T5 (es)	2000-03-30	2019-03-06	Whitehead Inst Biomedical Res	Mediadores de interferencia por ARN específicos de secuencias de ARN
US6673545B2 (en) *	2000-07-28	2004-01-06	Incyte Corporation	Prostate cancer markers
AU2002220920A1 (en) *	2000-12-08	2002-06-18	Oxford Biomedica (Uk) Limited	Method for identification of genes involved in specific diseases
WO2003010205A1 (en) *	2001-07-26	2003-02-06	Duke University Medical Center	Genes induced by hypoxia
EP2305836A1 (en) *	2002-08-20	2011-04-06	Millennium Pharmaceuticals, Inc.	Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
AU2003278112A1 (en) *	2002-10-18	2004-05-04	Silence Therapeutics Ag	Factor involved in metastasis and uses thereof
EP2319925B1 (en) *	2004-08-16	2018-07-25	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801

2003
- 2003-10-20 AU AU2003278112A patent/AU2003278112A1/en not_active Abandoned
- 2003-10-20 WO PCT/EP2003/011604 patent/WO2004035615A2/en not_active Ceased
- 2003-10-20 CA CA002501333A patent/CA2501333A1/en not_active Abandoned
- 2003-10-20 AT AT03769423T patent/ATE420102T1/de active
- 2003-10-20 BR BR0315411-4A patent/BR0315411A/pt not_active IP Right Cessation
- 2003-10-20 ES ES03769423T patent/ES2319891T3/es not_active Expired - Lifetime
- 2003-10-20 EP EP09000009A patent/EP2072619A1/en not_active Ceased
- 2003-10-20 PT PT03769423T patent/PT1551868E/pt unknown
- 2003-10-20 DK DK03769423T patent/DK1551868T3/da active
- 2003-10-20 US US10/531,726 patent/US20060240022A1/en not_active Abandoned
- 2003-10-20 CN CNB2003801016454A patent/CN100564524C/zh not_active Expired - Fee Related
- 2003-10-20 DE DE60325754T patent/DE60325754D1/de not_active Expired - Lifetime
- 2003-10-20 SI SI200331544T patent/SI1551868T1/sl unknown
- 2003-10-20 JP JP2004544275A patent/JP4820092B2/ja not_active Expired - Fee Related
- 2003-10-20 EP EP03769423A patent/EP1551868B1/en not_active Expired - Lifetime
- 2003-10-20 KR KR1020057006488A patent/KR101154130B1/ko not_active Expired - Fee Related
- 2003-10-20 MX MXPA05004134A patent/MXPA05004134A/es active IP Right Grant
2005
- 2005-03-24 ZA ZA2005/02483A patent/ZA200502483B/en unknown
- 2005-03-31 IL IL167801A patent/IL167801A/en not_active IP Right Cessation
2009
- 2009-03-26 CY CY20091100364T patent/CY1110313T1/el unknown
2010
- 2010-03-10 US US12/721,158 patent/US20100285038A1/en not_active Abandoned
- 2010-11-23 AU AU2010246370A patent/AU2010246370A1/en not_active Abandoned
- 2010-12-22 JP JP2010285811A patent/JP2011125339A/ja active Pending

Also Published As

Publication number	Publication date
CY1110313T1 (el)	2015-01-14
EP2072619A1 (en)	2009-06-24
WO2004035615A2 (en)	2004-04-29
US20100285038A1 (en)	2010-11-11
AU2010246370A1 (en)	2010-12-16
CN100564524C (zh)	2009-12-02
WO2004035615A3 (en)	2004-06-03
BR0315411A (pt)	2005-08-16
ZA200502483B (en)	2005-11-30
US20060240022A1 (en)	2006-10-26
ES2319891T3 (es)	2009-05-14
DE60325754D1 (de)	2009-02-26
EP1551868B1 (en)	2009-01-07
AU2003278112A1 (en)	2004-05-04
IL167801A (en)	2012-10-31
MXPA05004134A (es)	2005-10-05
PT1551868E (pt)	2009-04-06
KR20050056244A (ko)	2005-06-14
KR101154130B1 (ko)	2012-06-12
CA2501333A1 (en)	2004-04-29
JP2006520183A (ja)	2006-09-07
EP1551868A2 (en)	2005-07-13
SI1551868T1 (sl)	2009-06-30
JP2011125339A (ja)	2011-06-30
CN1705746A (zh)	2005-12-07
ATE420102T1 (de)	2009-01-15
JP4820092B2 (ja)	2011-11-24

Publication	Publication Date	Title
CY1110313T1 (el)	2015-01-14	Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al.	1999	Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Jiang et al.	1998	Pro-phenol oxidase activating proteinase from an insect, Manduca sexta: a bacteria-inducible protein similar to Drosophila easter
Leyh et al.	1992	The DNA sequence of the sulfate activation locus from Escherichia coli K-12.
DE69839768D1 (de)	2008-09-04	Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
EP1049767A4 (en)	2002-05-08	TRANSGENIC RABBIT EXPRESSING FUNCTIONAL HUMAN LIPOPROTEIN (A)
EP0821987A4 (en)	1998-06-10	METHOD FOR REGULATING CRYSTALLIZATION OF ORGANIC COMPOUNDS AND SEMICONDUCTOR COMPONENT FOR MODULATING CRYSTALLIZATION IN SAID PROCESS
AU1672388A (en)	1988-12-01	Expression of human proapolipoprotein a-i
DK0624641T3 (da)	2001-04-17	Termostabil nukleinsyrepolymerase
IS4884A (is)	1998-11-06	Ret bindill til örvunar vaxtar tauga og thvagfæra
NO20024240D0 (no)	2002-09-05	Nye arylfruktose-1,6-bisfosfataseinhibitorer
ATE528398T1 (de)	2011-10-15	Transkriptionsfaktor-gen osnacx aus reis und verwendung davon zur verbesserung der toleranz von pflanzen gegenüber trockenheit und salz
SE8801701D0 (sv)	1988-05-05	Production technology based on enzymic method
ATE464320T1 (de)	2010-04-15	Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
KR830003576A (ko)	1983-06-21	인간의 프로인슐린선구물질과 프로인슐린 유전자를 분리, 정제하고 미생물에게 전달해서 복제하는 방법
BR9811853A (pt)	2000-08-08	Processos para aumentar o rendimento em plantas
ATE431361T1 (de)	2009-05-15	Verwendung vom transportergen oatp-c zur screening von testsubstanzen
Nagata et al.	2005	Silk moth neuropeptide hormones: prothoracicotropic hormone and others
RU93031156A (ru)	1996-07-27	Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин
Chen et al.	2025	Elasticity of trachea in the silkworm: A role of gene BmMuc91C
ATE432996T1 (de)	2009-06-15	Verfahren zur bestimmung des bodenzustands
CY1110911T1 (el)	2015-06-10	Ανθρωπινο γονιδιο tsc403
WO2007120166A2 (en)	2007-10-25	Miniaturized in vitro protein expression array
Gillenwaters et al.	2009	Sequence analysis and polymorphism discovery in 4 members of the bovine cathelicidin gene family
ATE417066T1 (de)	2008-12-15	Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten